Source:http://linkedlifedata.com/resource/pubmed/id/12045460
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2002-6-4
|
| pubmed:abstractText |
A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were subsequently treated with adjuvant radiation therapy with (n=3) or without (n=7) concomitant chemotherapy. Therapy according to the study protocol consisted of mitoxantrone given as i.v. bolus on day 1 at a dose of 12 mg/m2 and cisplatin given as 90-min infusion at a dose of 30 mg/m2 on days 1-3. We observed two partial responses (14.3%) and stabilization of disease in nine patients (64.3%); progression during therapy was noted in only three cases (21.4%). The median time to progression was 15 months (range 2-36) and the median survival time was 27 months (range 4-54). Myelosuppression was commonly observed. Leukocytopenia occurred in all patients, and was grade 3 or 4 in three (21%) and four (29%) patients. WHO grade 3 thrombocytopenia and anemia was seen in three (21%) and four (29%) patients, respectively. Non-hematologic toxicity was in general mild to moderate except for two cases (14%) of grade 3 nausea and vomiting; overall incidence rates were nausea and vomiting (n=14), stomatitis (n=6), diarrhea (n=3), alopecia (n=11), infection (n=7), increase of serum creatinine (n=3), and peripheral neuropathy (n=3). The combination of mitoxantrone and cisplatin seems to be an active and fairly well-tolerated regimen for the treatment of advanced salivary gland cancers. According to the observed high rate of abrogating progressive disease for a long duration, and the resulting promising progression-free and overall survival time, further investigation seems warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0959-4973
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
491-5
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:12045460-Adult,
pubmed-meshheading:12045460-Aged,
pubmed-meshheading:12045460-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12045460-Chemotherapy, Adjuvant,
pubmed-meshheading:12045460-Cisplatin,
pubmed-meshheading:12045460-Disease-Free Survival,
pubmed-meshheading:12045460-Drug Administration Schedule,
pubmed-meshheading:12045460-Humans,
pubmed-meshheading:12045460-Lung Neoplasms,
pubmed-meshheading:12045460-Middle Aged,
pubmed-meshheading:12045460-Mitoxantrone,
pubmed-meshheading:12045460-Nausea,
pubmed-meshheading:12045460-Neoplasm Recurrence, Local,
pubmed-meshheading:12045460-Neutropenia,
pubmed-meshheading:12045460-Palliative Care,
pubmed-meshheading:12045460-Salivary Gland Neoplasms,
pubmed-meshheading:12045460-Survival Rate,
pubmed-meshheading:12045460-Treatment Outcome
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.
|
| pubmed:affiliation |
Department of Otorhinolaryngology, University of Vienna, 1090 Vienna, Austria.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|